Heyuan Biotech announced that in the first half of 2026, it achieved operating income of 18.2742 million yuan, a year-on-year increase of 43.77%; net loss attributable to shareholders of listed companies was 62.7565 million yuan, a decrease of 18.8813 million yuan over the same period last year; and R&D investment of 52.3852 million yuan, accounting for 286.66% of revenue. The core product, Ofumin®, is the first recombinant human albumin drug approved for marketing in China. It has passed the 2026 national medical insurance catalogue adjustment review. The enrollment of 2,000 patients in phase IV clinical trials has been completed, and international multi-center phase III clinical trials have begun. As of June 30, 2026, the balance of funds raised was 1,459 million yuan, and the use was in compliance; the controlling shareholder Yang Daichang held 11.27% of the shares, with no pledge, freeze or reduction of holdings.

Heyuan Biotech announced that in the first half of 2026, it achieved operating income of 18.2742 million yuan, a year-on-year increase of 43.77%; net loss attributable to shareholders of listed companies was 62.7565 million yuan, a decrease of 18.8813 million yuan over the same period last year; and R&D investment of 52.3852 million yuan, accounting for 286.66% of revenue. The core product, Ofumin®, is the first recombinant human albumin drug approved for marketing in China. It has passed the 2026 national medical insurance catalogue adjustment review. The enrollment of 2,000 patients in phase IV clinical trials has been completed, and international multi-center phase III clinical trials have begun. As of June 30, 2026, the balance of funds raised was 1,459 million yuan, and the use was in compliance; the controlling shareholder Yang Daichang held 11.27% of the shares, with no pledge, freeze or reduction of holdings.